Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | CASP6 | P55212 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193454 | 0.84 | CYP1A2 (0.61) | CYP1A2POLBKDM4ELMNACASP6 | |
| SCHEMBL30081474 | 0.84 | CYP1A2 (0.61) | CYP1A2POLBKDM4ELMNACASP6 | |
| SCHEMBL15831610 | 0.81 | BACE1 (0.45) | CYP1A2POLBKDM4EBACE1LMNA | |
| SCHEMBL985631 | 0.81 | CYP1A2 (0.47) | CYP1A2POLBKDM4EBACE1LMNA | |
| SCHEMBL15831571 | 0.80 | CCR1 (0.53) | CYP1A2POLBKDM4EBACE1LMNA | |
| SCHEMBL4889091 | 0.77 | BACE1 (0.63) | CYP1A2KDM4EBACE1LMNARAB9A | |
| SCHEMBL161703 | 0.77 | CYP1A2 (1.00) | CYP1A2POLBKDM4EBACE1LMNA | |
| SCHEMBL29444268 | 0.77 | CYP1A2 (1.00) | CYP1A2POLBKDM4EBACE1LMNA | |
| SCHEMBL10259445 | 0.76 | CYP1A2 (0.68) | CYP1A2POLBKDM4ELMNACASP6 | |
| SCHEMBL4058013 | 0.76 | CYP1A2 (0.56) | CYP1A2POLBKDM4ELMNACASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 335 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689627-B | Pyrazolylquinoline compounds, process for their preparation and pharmaceutical compositions containing them | 高雄医学大学 | 2022-10-11 | — | — | CN | claimed |
| CN-113754583-A | 2- ([2, 2' -biquinolyl ] -3-ether) -1-ethanol and derivative and synthetic method thereof | 湖南工程学院 | 2021-12-07 | — | — | CN | claimed |
| CN-113512064-A | Preparation method of aromatic phosphine oxide compound | 中南大学 | 2021-10-19 | — | — | CN | claimed |
| CN-110606839-B | Green synthesis method of polysubstituted quinazoline derivative | 南方医科大学 | 2021-10-08 | — | — | CN | claimed |
| CN-109776406-B | Method for cross coupling of ether compound and quinoline derivative | 湘潭大学 | 2021-05-04 | — | — | CN | claimed |
| CN-108912070-B | Synthetic method of epoxy compound and agricultural biological activity thereof | 青岛农业大学 | 2020-06-02 | — | — | CN | claimed |
| EP-2119717-B1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2018-01-17 | — | — | EP | claimed |
| US-8697868-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-04-15 | — | — | US | claimed |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | claimed |
| EP-1758905-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2009-04-29 | — | — | EP | claimed |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | claimed |
| EP-0245913-B1 | Process for preparing 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid | RIKER LABORATORIES, INC. (US) | 1992-03-25 | — | — | EP | claimed |
| US-4898945-A | Process for 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1990-02-06 | — | — | US | claimed |
| EP-0245913-A1 | Process for preparing 6,7-dihydro-5,8-dimethyl-9-fluoro-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid | RIKER LABORATORIES, INC. (US) | 1987-11-19 | — | — | EP | claimed |
| US-4301289-A | Process for 6,7-dihydro-9-fluoro-5-methyl-1-oxo-1H,5H-benzo(ij)quinolizine-2-carboxylic acid | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1981-11-17 | — | — | US | claimed |
| US-4301288-A | Process for 6,7-dihydro-9-fluoro-5-methyl-1-oxo-1H,5H-benzo(ij)quinolizine-2-carboxylic acid | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1981-11-17 | — | — | US | claimed |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-4301289-A | Process for 6,7-dihydro-9-fluoro-5-methyl-1-oxo-1H,5H-benzo(ij)quinolizine-2-carboxylic acid | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1981-11-17 | — | — | US | disclosed |
| US-4207320-A | FUNGICIDES | WARNER-LAMBERT COMPANY (US) | 1980-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | CYP1A2 3894/4885POLB 4265/4885KDM4E 465/4885 |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP7 | CYP1A2 592/4885POLB 2194/4885KDM4E 1036/4885 |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | CYP1A2 3894/4885POLB 4265/4885KDM4E 465/4885 |
| US-20050234108-A1 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | DPP8, DPP4, DPP7 | CYP1A2 616/4885POLB 2648/4885KDM4E 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.